MD Nora Nikander joins Abomics’ Medical Advisory team, bringing clinical experience from university hospital care and a strong focus on pharmacogenetics. Her expertise supports the development of practical, clinically relevant tools that enable safer, individualized prescribing in everyday healthcare.
The Abomics team has been strengthened with a new addition, as MD Nora Nikander has joined our Medical Advisory team. She previously worked as a physician at Turku University Hospital. Nora has a strong interest in personalized medicine and pharmacogenetics, and she brings with her valuable clinical expertise.
In her role as Medical Advisor, Nora will contribute to the development and implementation of pharmacogenetic tools that support healthcare professionals in making safer, more individualized medication decisions. Her clinical insight will help ensure that our solutions remain practical, relevant, and truly beneficial for both doctors and patients.
Abomics collaborates with clinical laboratories, clinical research organizations, electronic health record (EHR) providers, genetics companies, and biobanks to deliver pharmacogenetic interpretation services and personalized pharmacogenetic reports. These tools help physicians select the most appropriate medication and dosage based on a patient’s genetic profile.
Abomics also develops medical and pharmaceutical databases that support clinicians in making informed prescribing decisions. In early 2025, Abomics completed its merger with Multirec, a company with over 20 years of experience in providing drug databases and clinical decision support for electronic health records. Multirec’s strong reputation and long-standing partnerships with leading EHR vendors enhance Abomics’ ability to integrate pharmacogenetics into routine clinical workflows in a user-friendly and effective way.
Abomics has appointed a new Lead Bioinformatician to deepen its expertise in genomics and pharmacogenetics. The role strengthens scientific capabilities behind clinically actionable solutions and supports the practical implementation of precision medicine in healthcare settings.
Abomics has renewed its ISO 13485:2016 certification, confirming that its pharmacogenetic reporting and clinical decision support solutions meet internationally recognized quality standards. The certification reinforces consistent, risk-based processes that support safe and reliable implementation.
Abomics strengthens its leadership team to support continued growth in precision medicine. New commercial and business development expertise reinforces the company’s ability to expand strategic partnerships and deliver clinically integrated pharmacogenetic solutions that advance personalized healthcare in real-world settings.